company background image
SPRINT

Sprint Bioscience OM:SPRINT Stock Report

Last Price

kr0.71

Market Cap

kr49.3m

7D

1.9%

1Y

-84.1%

Updated

09 Feb, 2023

Data

Company Financials +

Sprint Bioscience AB (publ)

OM:SPRINT Stock Report

Mkt Cap: kr49.3m

SPRINT Stock Overview

Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism in Sweden, Europe, the United States, and Asia.

SPRINT fundamental analysis
Snowflake Score
Valuation4/6
Future Growth3/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

New

Notes are coming soon

Sprint Bioscience AB (publ) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Sprint Bioscience
Historical stock prices
Current Share Pricekr0.71
52 Week Highkr4.69
52 Week Lowkr0.49
Beta1.32
1 Month Change4.28%
3 Month Change0.86%
1 Year Change-84.13%
3 Year Change-93.70%
5 Year Change-95.52%
Change since IPO-95.59%

Recent News & Updates

Recent updates

Is Sprint Bioscience (STO:SPRINT) In A Good Position To Deliver On Growth Plans?

Nov 19
Is Sprint Bioscience (STO:SPRINT) In A Good Position To Deliver On Growth Plans?

Shareholder Returns

SPRINTSE BiotechsSE Market
7D1.9%-0.2%-2.4%
1Y-84.1%-2.5%-12.8%

Return vs Industry: SPRINT underperformed the Swedish Biotechs industry which returned -4.1% over the past year.

Return vs Market: SPRINT underperformed the Swedish Market which returned -12.2% over the past year.

Price Volatility

Is SPRINT's price volatile compared to industry and market?
SPRINT volatility
SPRINT Average Weekly Movement12.1%
Biotechs Industry Average Movement8.6%
Market Average Movement6.6%
10% most volatile stocks in SE Market12.6%
10% least volatile stocks in SE Market3.8%

Stable Share Price: SPRINT is more volatile than 75% of Swedish stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: SPRINT's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Swedish stocks.

About the Company

FoundedEmployeesCEOWebsite
200934Mathias Skalmstadhttps://www.sprintbioscience.com

Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism in Sweden, Europe, the United States, and Asia. It engages in developing VPS34, a drug candidate for the treatment of various types of cancer; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism and type 2 diabetes.

Sprint Bioscience AB (publ) Fundamentals Summary

How do Sprint Bioscience's earnings and revenue compare to its market cap?
SPRINT fundamental statistics
Market Capkr49.28m
Earnings (TTM)-kr60.41m
Revenue (TTM)kr803.00k

61.4x

P/S Ratio

-0.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SPRINT income statement (TTM)
Revenuekr803.00k
Cost of Revenuekr12.87m
Gross Profit-kr12.07m
Other Expenseskr48.34m
Earnings-kr60.41m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.87
Gross Margin-1,503.24%
Net Profit Margin-7,522.67%
Debt/Equity Ratio0%

How did SPRINT perform over the long term?

See historical performance and comparison